3DIARRA D, STOLINA M, POLZER K, et al. Dickkopf-1 is a master regulator of joint remodeling [ J ]. Nat Med, 2007, 13 (2): 156-163.
4RUDWALEIT M, SCHWARZLOSE S, HILGERT E S, et al. MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spondylitis [J]. Ann Rheum Dis, 2008, 67 (9): 1276-1281.
5GIARDINA A, CICCIA F, PRINCIPATO A, et al. Patients with short duration (5 years) ankylosing spondylitis respond rapidly and maintain partial remission over a two years period when treated with TNF-blocking agents [ J ]. Ann Rheum Dis, 2008, 67 (Suppl Ⅱ ) : 624.
6BARKHAM N, KEEN H I, COATES L C, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positire patients with magnetic resonance imaging-determined early sacroiliitis[J]. Arthritis Rheum, 2009, 60 (4): 946- 954.
7HAIBEL H, RUDWALEIT M, LISTING J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo- controlled trial followed by an open-label extension up to week fifty-two [ J ]. Arthritis Rheum, 2008, 58 ( 7 ) : 1981-1991.
8BARALIAKOS X, LISTING J, BRANDT J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab [ J ]. Arthritis Res Ther, 2005, 7 (3) : R439-R444.
9AMTENBRINK A, HAIBEL H, RUDWALEIT M, et al. Adalimumab successfully re-treats and maintains long-term efficacy in axial spondyloarthritis (SpA) patients without radiogTaphic sacroiliitis who relapse following adalimumab withdrawa[J]. Arthritis Rheum, 2008, 58 (Suppl 9) :S304.
7Karkucak M, Capkin E, Alver, A, et, al. The effect of anti - TNF agent on oxidation stahus in patients with ankylosing spondylitis [ J ]. Clin Rheumatol,2010,29 (3) :303 - 307.
9Karkucak M,Capkin E,Alver,A. The effect of antiTNF agent on oxidation stahus in patients with ankylosing spondylitis[J].Clinical Rheumatology,2010,(03):303-307.
